7,752 reports of this reaction
2.6% of all Xarelto reports
#3 most reported adverse reaction
HAEMORRHAGE is the #3 most commonly reported adverse reaction for Xarelto, manufactured by Janssen Pharmaceuticals, Inc.. There are 7,752 FDA adverse event reports linking Xarelto to HAEMORRHAGE. This represents approximately 2.6% of all 302,183 adverse event reports for this drug.
Patients taking Xarelto who experience haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMORRHAGE is a less commonly reported adverse event for Xarelto, but still significant enough to appear in the safety profile.
In addition to haemorrhage, the following adverse reactions have been reported for Xarelto:
The following drugs have also been linked to haemorrhage in FDA adverse event reports:
HAEMORRHAGE has been reported as an adverse event in 7,752 FDA reports for Xarelto. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMORRHAGE accounts for approximately 2.6% of all adverse event reports for Xarelto, making it one of the most commonly reported side effect.
If you experience haemorrhage while taking Xarelto, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.